1556 search results for “drug safety” in the Public website
-
Drug safety Sciences
Our research in the area of safety sciences aims to increase the mechanistic understanding of cellular toxicity of drugs and, in a broader sense, chemicals.
-
Cancer Therapeutics and Drug Safety
In this research group, headed by Bob Van de Water, cell signaling programs that underlie adverse drug reactions as well as cancer development and progression are unraveled. Adverse drug reactions involve cell injury in critical target organ cells which leads to the activation of cellular stress response…
-
Drug Discovery & Safety
In the research programme Drug Discovery & Safety, we are interested in the efficacy and safety of new drugs and novel means to decipher these aspects. Hence, we employ advanced imaging and high-throughput screening techniques next to computational approaches such as chem- and bioinformatics.
-
Division of Drug Discovery & Safety
We are interested in the efficacy and safety of new drugs and novel means to decipher these aspects. Hence, we employ advanced imaging and high-throughput screening techniques next to computational approaches such as chem- and bioinformatics.
-
Drug Discovery and Safety (MSc)
The master's specialisation Drug Discovery and Safety at Leiden University provides students with research-oriented education into the discovery of new drug targets and new lead molecules, particularly in the field of cancer, through a combination of advanced imaging techniques (‘systems microscopy’),…
-
Unravelling cancer drug resistance mechanisms
Mechanisms fro drug resistance
-
Systems pharmacology-based translational drug pharmacokinetics
High-throughput holistic preclinical screens are increasingly used in drug discovery, to assess both drug efficacy and drug safety.
-
Leiden Academic Centre for Drug Research
Drug development is a complex process in which many parties work together. Every day, the researchers at LACDR devote their energies to developing drugs that are new, better, more efficient and easier to produce. And thus to the millions of patients who know all too well why this research in Leiden…
-
Advanced in vitro models for studying drug induced toxicity
Promotor: Prof.dr. B. van de Water, Co-promotor: L.S. Price
-
Leiden Academic Centre for Drug Research
The Leiden Academic Centre for Drug Research (LACDR) is a centre of excellence for multidisciplinary research on drug discovery and development.
-
Translational drug discovery and development
We cover the entire spectrum from target identification to the evaluation of the efficacy and safety of novel medicines in clinical practice.
-
Drug-Related Homicide in Europe
Drug-related homicide (DRH) has the potential to act as a valuable indicator of wider drug-related crime. Yet DRH remains a knowledge gap within this broader field of study.
-
generation human IPSC-derived reporter systems for image-based analysis of drug adversity
Analysis of drug adversity
-
throughput microscopy for cellular adaptive stress response pathways in drug adversity
High throughput microscopy
-
Collaborative and effective drug development
There are many complex links in the chain that provides patients with new drugs: from fundamental science, to clinical tests, to production. The entire chain can be found in Leiden. The University, the Leiden University Medical Center (LUMC) and the businesses at the Leiden Bio Science Park (LBSP) work…
-
Reverse engineering of drug induced QT(c) interval prolongation: Towards a systems pharmacology approach
Promotor: M. Danhof Co-promotor: O.E. Della Pasqua
-
Safety First
You can find more information on the Dutch webpage. Click on the “Nederlands” button above.
-
Bob van de Water
Science
-
Towards predictive cardiovascular safety: a systems pharmacology approach
Promotores: Prof.dr. M. Danhof, Prof.dr. D.R. Stanski
-
Novel immunomodulatory drugs for tuberculosis treatment
Can drugs that target host signaling pathways be used to eradicate antibiotic-resistant bacteria?
-
Novel target engagement biomarkers for better drug candidates
Is is possible to better predict the validity of drug candidates?
-
Youth and safety
Policy studies and interventions in the field of Youth
-
Data-Driven Drug Discovery Network (D4N)
The Data-Driven Drug Discovery Network (D4N) is an initiative by researchers from Leiden University and collaborators to join efforts in applying and developing novel techniques from data science to drug discovery and related topics from bioinformatics. The network is embedded in the Leiden Centre of…
-
Cancer Drug Target Discovery
We focus on a better understanding of the mechanisms of cancer drug resistance and metastasis.
-
Mechanistic modelling of drug target binding kinetics as determinant of the time course of drug action in vivo
Drug-target binding kinetics determine the time course of the central event in pharmacotherapy: Drug-target interaction.
-
Cancer Drug Target Discovery
In this research group, headed by Prof. Erik Danen, the aim is to unravel cellular signaling mechanisms in normal and diseased cells, with a long-standing interest in cell adhesion signaling. In complex multicellular organisms such as ourselves, a division of labor emerges where different tissues and…
-
Dynamics of TNFalpha signaling and drug-related toxicity
In previous studies at our laboratory it was demonstrated that drug exposure of HepG2 cells can lead to an altered TNFα-induced NF-κB oscillatory phenotype, concurrent with a synergistically increased sensitivity for TNFα-induced apoptosis.
-
Computational Drug Discovery
Research in this group, headed by Gerard van Westen, focusses on computational methods integrated in different parts of the drug discovery process. More specifically, topics include innovative treatments for cancer, selectivity modeling, translational research, allosteric modulation, drug resistance…
-
Assessing the safety of chemicals and medicines without laboratory animals
One of the holy grails of drug research is to be able to assess the safety of chemicals and pharmaceuticals without using laboratory animals. Researchers from Leiden University, among others, now receive a grant from the National Science Agenda to pursue that goal.
-
Pharmacogenomics in drug development: implementation and application of PKPD model based approaches
Promotor: Prof.dr. M. Danhof, Co-Promotor: J. de Jongh
-
pharmacognostic study of Vernonia guineensis Benth. (Asteraceae): bioactivity, safety, and phytochemical analysis
Promotor: Prof.dr. R. Verpoorte, , Co-Promotor: Young Hae Choi
-
Regional Aviation Safety Organisations: Enhancing Air Transport Safety through Regional Cooperation
Aviation safety is of global concern. Yet 43% of countries worldwide lack the expertise and administrative capacity to ensure effective safety oversight of the aviation activities for which they are responsible under international law.
-
Youth and safety
Policy studies and interventions in the field of Youth
-
Prediction of spatial-temporal brain drug distribution with a novel mathematical model
A novel mathematical model describes spatial-temporal drug distribution within one or more brain units, which are cubic representations of a piece of brain tissue with brain capillaries at the edges.
-
Systems microscopy to unravel cellular stress response signalling in drug induced liver injury
Promotor: B. van de Water
-
Microneedle-based drug and vaccine delivery via nanoporous microneedle arrays
In the literature, several types of microneedles have been extensively described. However, porous microneedle arrays only received minimal attention. Hence, only little is known about drug delivery via these microneedles. However, porous microneedle arrays may have potential for future microneedle-based…
-
Kinetics for drug discovery – The first step towards an improved drug discovery paradigm
Supervisor: Indira Nederpelt
-
Contact
Division contact information & address
-
Discovery of metastasis promoting candidate drug targets
Discovery of metastasis promoting candidate drug targets
-
Drug-target binding kinetics in vivo
A next, general pharmacological problem to be tackled is how drug-target binding kinetics in vivo, affects target occupancy as an important indicator of the time-course of drug effects.
-
Activity-based protein profiling in drug discovery
In the last decades, activity-based protein profiling (ABPP) has emerged as a powerful chemical tool that may aid the ever-challenging drug discovery process.
-
About the programme
Drug Discovery and Safety consists of 120 European Credit Transfer System (EC) points.
-
Inter-Organizational Collaboration and Innovation in the Public Safety Sector
What are the various forms of inter-organizational collaboration in the public safety sector? How are different forms of inter-organizational collaborative arrangements related? What is the relationship between inter-organizational collaboration and innovation in the public safety sector?
-
Postdoctoral researcher in computational drug discovery
Science, Leiden Academic Centre for Drug Research (LACDR)
-
Professor in Stem cell technology for innovative drug research
Science, Leiden Academic Centre for Drug Research (LACDR)
-
Novel insights into old anticancer drugs
PhD Defence
-
Why Leiden University?
We are committed to provide you with meaningful, rigorous and quality graduate experiences in a personalized environment with a cutting edge research infrastructure and internationally renowned supervisors.
-
Maarten Doornbos - Drug binding kinetics as predictor of potential medicines
Faster development of efficacious medicines; that is the goal of molecular pharmacologist Maarten Doornbos of the Leiden Academic Centre for Drug Research. He wants to find out which mechanisms influence the binding of drugs to a promising drug target in the body. That way, it will become easier to…
-
Spatial (3-D) CNS drug distribution in vivo
Another research line is the development of a spatial CNS drug distribution model, by ultimately including the 3-dimensional anatomical organization of the CNS.
-
Quan/Qual analysis of drugs and metabolites in biological matrices
Can we develop a generic method for Quan/Qual analysis of small molecule drugs, their metabolites and endogenous metabolites in (pre-)clinical samples?